• 1
    Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853860.
  • 2
    Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 11121115.
  • 3
    Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492497.
  • 4
    Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240247.
  • 5
    Gordon RD, Van Thiel DH, Starzl TE. Liver transplantation. In: SchiffL, SchiffER, eds. Diseases of the Liver, 7th Ed. Philadelphia : JB Lippincott, 1993: 12101235.
  • 6
    Fung JJ, Eghtesad B, Patel-Tom K, De Vera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl 2004; 10(Suppl): S39S53.
  • 7
    Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239247.
  • 8
    Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 14121420.
  • 9
    Prachalias AA, Pozniak A, Taylor C et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001; 72: 16841688.
  • 10
    Stock PG, Roland ME, Carlson L et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: A pilot safety and efficacy study. Transplantation 2003; 76: 370375.
  • 11
    Norris S, Taylor C, Muiesan P et al. Outcomes of liver transplantation in HIV-infected individuals: The impact of HCV and HBV infection. Liver Transpl 2004; 10: 12711278.
  • 12
    Radecke K, Frühauf NR, Miller M et al. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver Int 2005; 25: 101108.
  • 13
    Tolan DJ, Davies MH, Millson CE. Fibrosing cholestatic hepatitis after liver transplantation in a patient with hepatitis C and HIV infection. N Engl J Med 2001; 345: 1781.
  • 14
    Moreno S, Fortun J, Quereda C et al. Liver transplantation in HIV-infected recipients. Liver Transpl 2005; 11: 7681.
  • 15
    De Vera ME, Eghtesad B, Jain A, Dodson SF, Fung JJ, Bonham CA. Liver transplantation in patients co-infected with HIV and hepatitis C [Abstract]. Am J Transpl 2002; 2: S3, 139.
  • 16
    Marcos A, Eghtesad B, Fung JJ et al. The use of alemtuzumab in a tolerogenic protocol for cadaveric liver transplantation. Transplantation 2004; 78: 966971.
  • 17
    Starzl TE, Murase N, Abu-Elmagd K et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 14891490.
  • 18
    Kusne S, Grossi P, Irish W et al. Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999; 68: 11251131.
  • 19
    Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 20
    Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666678.
  • 21
    Sulkowski M, Mehta S, Torbenson M et al. Unexpected significant liver disease among HIV/HCV co-infected persons with minimal fibrosis on initial liver biopsy. Abstract 121, Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, February 22–25, 2005, Boston , MA .
  • 22
    Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 15.
  • 23
    Erice A, Rhame FS, Heussner RC, Dunn DL, Balfour HH. Human immunodeficiency virus infection in patients with solid-organ transplants: Report of five cases and review. Rev Infect Dis 1991; 13: 537547.
  • 24
    Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE. Transplantation in HIV+ patients. Transplantation 1990; 49: 354358.
  • 25
    Paya CV, Razonable RR. Cytomegalovirus infection after solid organ transplantation. In: Bowden RA , LjungmanP, PayaCV, eds. Transplant Infections. Philadelphia , PA : Lippincott, Williams, & Wilkins, 2003: 229244.
  • 26
    Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005; 11: 479489.
  • 27
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 28
    Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 29
    Charlton M. Retransplantation for HCV—the view through a broken crystal ball. Liver Transpl 2005; 11: 382383.
  • 30
    Llado L, Castellote J, Figueras J. Is retransplantation an option for recurrent hepatitis C cirrhosis after liver transplantation? J Hepatol 2005; 42: 468472.
  • 31
    Schluger LK, Sheiner PA, Thung SN et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971976.
  • 32
    Duclos-Vallee J-C, Vittecoq D, Teicher E et al. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J Hepatol 2005; 42: 341349.
  • 33
    Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8(Suppl): S19S27.
  • 34
    Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transpl 2006; 6: 753760.
  • 35
    Den Brinker M, Wit FW, Wertheim-van Dillen PM et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 28952902.
  • 36
    Testa G, Crippin JS, Netto GJ et al. Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553561.
  • 37
    Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 38
    Boker KHW, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trautwein C. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25: 203210.
  • 39
    De Vera ME, Smallwood GA, Rosado K et al. Interferon-α and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71: 678686.
  • 40
    Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transpl 2004; 18: 166173.
  • 41
    Neff GW, Montalbano M, O'Brien CB et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 13031307.
  • 42
    Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transpl 2006; 6: 449458.